Insights

Leveraging the immunological diversity of the PentaMice® platform for COVID-19 antibody discovery

icons/content-types/white paper white paper

Biologics Discovery

Hybridoma technology is a popular method for antibody discovery, but the conventional approach of using a single inbred mouse strain for immunization fails to generate the diversity and antibody titers needed to maximize the discovery of high-quality leads. This white paper introduces an alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and highlights how Curia is leveraging it for COVID-19 antibody discovery.

Download our white paper for insights on:

  • The PentaMice platform
  • Discovering SARS-CoV-2 variant-specific antibodies
  • Discovering diverse, high-quality antibodies against SARS-Cov-2

Download the White Paper

Ready to move from idea to impact?

Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.

Contact Us
More from Curia

040E93C7-D189-4233-A102-58C0580BE529 publications patents

Poster: In Vitro Characterization of a Dual Antagonistic Anti-LILRB2/LILRB4 Monoclonal Antibody

We have identified a dual antiLILRB2/LILRB4 antagonist. Targeting MDSCs with this antibody offers great promise for immunotherapy for cancer as well as its immense potential for synergy with PD-1 blockade.

icons/content-types/article article

Trends and Challenges in the Pharmaceutical Industry

Significant changes have taken place in the life sciences industry over the past few years. Since the Covid-19 pandemic, the U.S. government has urged biotech and pharmaceutical companies to increase domestic production in order to secure the drug su...